Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group.

Abstract

Multiple factors differentially influence treatment decisions in the first line treatment of recurrent/metastatic HNSCC. The EORTC Young investigator group launched a survey among treating physicians to explore the main influencing factors for treatment stratification. The questionnaire was posted as a web-survey link from May to August 2020. Next to defining the factors that mostly influence therapeutic decision the survey was complemented by a clinical case discussion of five patient cases. A total of 118 responses from 19 countries were collected. The key factors identified to guide treatment decision were performance status, PD-L1 Expression, time from last systemic treatment above or below 6 months, and disease burden. Prospective evaluation of patient characteristics and additional potential predictive biomarkers for novel treatment options remains an important question to stratify personalized treatment for RM HNSCC.

• Authors: Konrad Klinghammer, Luigi Lorini, Daan Nevens, Christian Simon, Jean-Pascal Machiels, Paolo Bossi
• Journal: Frontiers in oncology (Front Oncol) Vol. 12 Pg. 730785 ( 2022) ISSN: 2234-943X [Print] Switzerland
• PMID: 35155222 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Klinghammer, Lorini, Nevens, Simon, Machiels and Bossi.